The New Era of Neuromyelitis Optica Spectrum Disorder: Advances in Diagnosis and Treatment
Special Considerations

0.25 CME
0.25 CPE
$0 FEE
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

podcast 4


Release date: 10/21/2020
Expiration date: 10/21/2021

Provider Statement

This activity is jointly provided by The Consortium of Multiple Sclerosis Centers and Catamount Medical Education.

Activity Description

In this activity, expert faculty examine special considerations in the treatment of NMOSD, including the impact of other autoimmune diseases and treatment in the context of the current COVID-19 pandemic.

Target Audience

The target learning audience for this initiative is neurologists, nurses, nurse practitioners, PAs, pharmacists, and other members of the healthcare team essential to the diagnosis and management of patients with neuromyelitis optica spectrum disorder.

Learning Objective

At the conclusion of this activity, participants should be better able to: 

  • Apply evidence-based approaches to personalizing treatment for patients with NMOSD


Brian G. Weinshenker, MD, FRCP(C)
Consultant, Department of Neurology
Professor of Neurology, College of Medicine
Mayo Clinic
Rochester, MN

Marcelo Matiello, MD
Assistant Professor of Neurology, Harvard Medical School
Director, Massachusetts General Hospital Neurology Inpatient Services
Director, Massachusetts General Hospital Routine and Urgent Teleneurology Program
Associate Director, Neuromyelitis Optica Clinic and Research Unit
Boston, MA

Planning Committee

June Halper, MSN, APN-C, MSCN, FAAN, Consortium of Multiple Sclerosis Centers
Laurie Scudder, DNP, NP, Consortium of Multiple Sclerosis Centers
Tina Trott, Continuing Professional Education Manager, Consortium of Multiple Sclerosis Centers
Susan Denner MD, MS, Medical Director, Catamount Medical Education 
Jennifer Green, Chief Learning Officer, Catamount Medical Education
Melissa Jozefiak, Project Manager, Catamount Medical Education 


In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC) and Catamount Medical Education. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Credit Designation

The CMSC designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit Designation
The CMSC designates this activity for a maximum of 0.25 contact hours of continuing nursing education (0.25 in the area of pharmacology).

This knowledge-based activity, UAN JA4008165-9999-20-053-H01-P, qualifies for 0.25 contact hours (.025 CEUs) of continuing pharmacy education credit.
Upon successful completion of the activity, your CE credits will be submitted electronically to the NABP CPE Monitor service.  Paper certificates are not valid.  For information about CPE Monitor, visit

How to Participate in This Activity and Obtain CE Credit

There are no fees for participating and receiving credit for this activity. During the period that the activity is available for credit, participants must:

1) Read the CE information
2) Complete the pre-test
3) Listen to the podcast
4) Complete the post-test and the evaluation form

A score of 100% correct must be achieved on the post-test to successfully complete the activity. If you do not receive a passing score, you will receive a message notifying you that you did not pass the post-test. You may retake the post-test until successful. Following the post-test and evaluation form your certificate will be made available immediately. 


It is the policy of the Consortium of Multiple Sclerosis Centers (CMSC) to ensure balance, independence, objectivity, and scientific rigor in all educational activities. All faculty, planning committee members, content reviewers, and staff participating in this activity have disclosed any relevant financial relationships they or their significant other have had within the previous 12 months with manufacturers of any commercial products/devices and/or providers of commercial services included in this educational activity. The intent of this disclosure is not to prevent a person with a relevant financial relationship from participating in the activity, but rather to provide participants with information on which they can base their own judgments.  All presentations were reviewed by an independent clinician with no relevant financial relationships for the purpose of resolution of any identified conflict of interest and a determination of evidence-base and fair balance.

Faculty Disclosures:

Brian G. Weinshenker, MD, FRCP(C)

Dr. Weinshenker has disclosed the following relationships:

  • Royalty: RSR Ltd, Oxford University, Hospices Civil de Lyon, MVZ Labor PD Dr. Volkmann Kollegen GbR
  • Receipt of Intellectual Property Rights/Patent Holder: Patent for use of NMO-IgG as diagnostic test for neuromyelitis optica spectrum disorder
  • Consulting Fee: Chugai/Roche/Genentech re satralizumab clinical trial; Mitsubishi Tanabe re trial design
  • Fees for Non-CME/CE Services Received Directly from a Commercial Interest or its Agent: Genentech
  • Other: Chair for attack adjudication committee for Alexion and MedImmune/Viela Bio

Marcelo Matiello, MD

Dr. Matiello has disclosed the following relationships:

  • Consulting Fee: Vielabio

Accreditor and Planning Committee Disclosures:

June Halper, MSN, APN-C, MSCN, FAAN, has declared that she has no relevant financial relationships to disclose.
All other planners, reviewers, staff, or other members of the Continuing Professional Education Committee at the Consortium of Multiple Sclerosis Centers who control content have disclosed no relevant financial relationships.
Laurie Scudder, DNP, NP, has served as Nurse Planner for this activity. She has declared that she has no relevant financial relationships to disclose.

Publishing Staff Disclosures:

The planners, reviewers, editors, staff, CME committee, or other members at Catamount Medical Education who control content have disclosed no relevant financial relationships.

Disclosure of Unlabeled Use

CMSC and Catamount Medical Education require CE faculty (speakers) to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

During this presentation, Dr. Weinshenker may reference rituximab, tocilizumab, and other immunosuppressant medications to treat neuromyelitis optica spectrum disorder. Dr. Matiello may reference azathioprine, prednisone, mycophenolate mofetil, methotrexate, mitoxantrone, and plasmapheresis.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

For CME/CE questions, please contact Catamount Medical Education:

Privacy Policy 

The Consortium of Multiple Sclerosis Centers and Catamount Medical Education, LLC, respect your privacy. All personal information that is provided to Catamount Medical Education, LLC, is protected and will not be sold to a third party for commercial purposes. All personally identifiable information contained in the Catamount Medical Education, LLC, registration databases is treated as confidential and will be used only for the purposes stated in this policy, except where required by law. Catamount Medical Education, LLC, maintains user databases that contain mailing and user profile information as well as a record of the CME activities viewed and the post-test and evaluation results for CME/CNE credit. This information is provided to activity collaborators for the purposes of CME/CNE recordkeeping. By participating in this activity, you agree that Catamount Medical Education, LLC, has full permission to provide this information.

Catamount Medical Education, LLC, safeguards against the loss, misuse, or alteration of information that we have collected in this activity.